Alnylam Pharmaceuticals, Inc.ALNYNASDAQ
Loading
Operating Income Growth Under PressureDecelerating
Percentile Rank8
Year-over-Year Change
Year-over-year operating income growth rate
Percentile
P8
Near historical low
vs 5Y Ago
-4.7x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -64.21% |
| Q3 2025 | 2371.63% |
| Q2 2025 | -189.61% |
| Q1 2025 | 117.19% |
| Q4 2024 | -36.74% |
| Q3 2024 | -258.20% |
| Q2 2024 | 211.92% |
| Q1 2024 | 62.69% |
| Q4 2023 | -154.43% |
| Q3 2023 | 193.05% |
| Q2 2023 | -53.42% |
| Q1 2023 | 20.57% |
| Q4 2022 | 26.91% |
| Q3 2022 | -34.62% |
| Q2 2022 | -30.64% |
| Q1 2022 | 24.58% |
| Q4 2021 | -7.09% |
| Q3 2021 | -24.30% |
| Q2 2021 | 21.53% |
| Q1 2021 | 4.10% |
| Q4 2020 | 13.76% |
| Q3 2020 | -13.25% |
| Q2 2020 | 5.38% |
| Q1 2020 | 29.49% |
| Q4 2019 | -37.81% |
| Q3 2019 | 8.45% |
| Q2 2019 | -25.15% |
| Q1 2019 | 14.33% |
| Q4 2018 | 13.44% |
| Q3 2018 | -32.34% |
| Q2 2018 | -30.49% |
| Q1 2018 | -0.07% |
| Q4 2017 | -17.09% |
| Q3 2017 | -4.42% |
| Q2 2017 | -13.11% |
| Q1 2017 | 7.73% |
| Q4 2016 | -8.21% |
| Q3 2016 | -15.39% |
| Q2 2016 | 15.98% |
| Q1 2016 | -18.93% |